Daniel Drucker
@danieljdrucker.bsky.social
A clinician scientist at LTRI @sinaihealth studying Glucagon, GIP, GLP-1, GLP-2, diabetes, obesity, metabolism and the gut endocrine system
The daily torrent of real world data continues. Here (lower) rates of suicidal ideation, depression and anxiety in children treated with GLP-1 medicines in Florida 🧪https://www.medrxiv.org/content/10.1101/2025.11.11.25339931v1
November 27, 2025 at 11:20 AM
The daily torrent of real world data continues. Here (lower) rates of suicidal ideation, depression and anxiety in children treated with GLP-1 medicines in Florida 🧪https://www.medrxiv.org/content/10.1101/2025.11.11.25339931v1
Here the authors highlight the therapeutic potential of targeting adipocyte TGR5 for MASLD intervention 🧪https://diabetesjournals.org/diabetes/article/doi/10.2337/db25-0344/163910/Adipose-TGR5-Deletion-Promotes-Hepatic-Steatosis ada.silverchair-cdn.com/ada/content_...
November 27, 2025 at 3:11 AM
Here the authors highlight the therapeutic potential of targeting adipocyte TGR5 for MASLD intervention 🧪https://diabetesjournals.org/diabetes/article/doi/10.2337/db25-0344/163910/Adipose-TGR5-Deletion-Promotes-Hepatic-Steatosis ada.silverchair-cdn.com/ada/content_...
New top line P2 data for Amycretin, a unimolecular agonist of the glucagon-like peptide 1 (GLP-1) and amylin receptors, intended for once-weekly subcutaneous administration and once-daily oral administration, in PPL with #T2D #weightloss
www.novonordisk.com/content/nnco...
www.novonordisk.com/content/nnco...
November 25, 2025 at 11:40 AM
New top line P2 data for Amycretin, a unimolecular agonist of the glucagon-like peptide 1 (GLP-1) and amylin receptors, intended for once-weekly subcutaneous administration and once-daily oral administration, in PPL with #T2D #weightloss
www.novonordisk.com/content/nnco...
www.novonordisk.com/content/nnco...
Beyond the bacterial #microbiome a new focus on harnessing the gut non-bacterial microbial entities in the therapeutics and prevention of metabolic diseases www.sciencedirect.com/science/arti...
November 25, 2025 at 11:29 AM
Beyond the bacterial #microbiome a new focus on harnessing the gut non-bacterial microbial entities in the therapeutics and prevention of metabolic diseases www.sciencedirect.com/science/arti...
Oral semaglutide disappoints in the two evoke trials, failing to reduce the rate of cognitive decline #Alzheimers disease #Dementia www.novonordisk.com/content/nnco...
November 24, 2025 at 11:31 AM
Oral semaglutide disappoints in the two evoke trials, failing to reduce the rate of cognitive decline #Alzheimers disease #Dementia www.novonordisk.com/content/nnco...
A reminder of the primary endpoint in the evoke trials, the change in the CDR – Sum of Boxes (CDR-SB) score from baseline to week 104 #Alzheimers www.understandingalzheimersdisease.com/-/media/File...
November 22, 2025 at 11:58 AM
A reminder of the primary endpoint in the evoke trials, the change in the CDR – Sum of Boxes (CDR-SB) score from baseline to week 104 #Alzheimers www.understandingalzheimersdisease.com/-/media/File...
As disclosure of evoke and evoke+ trial results for oral semaglutide in people with imaging or biomarker+ #Alzheimers disease approaches, a reminder of the primary and secondary endpoints alzres.biomedcentral.com/articles/10....
November 22, 2025 at 11:46 AM
As disclosure of evoke and evoke+ trial results for oral semaglutide in people with imaging or biomarker+ #Alzheimers disease approaches, a reminder of the primary and secondary endpoints alzres.biomedcentral.com/articles/10....
Human #genetic evidence in humans is consistent with direct TAS2R38 actions in postprandial glycemia, supporting TAS2R38 as a novel therapeutic target for glucose regulation.
diabetesjournals.org/diabetes/art...
diabetesjournals.org/diabetes/art...
November 21, 2025 at 11:27 AM
Human #genetic evidence in humans is consistent with direct TAS2R38 actions in postprandial glycemia, supporting TAS2R38 as a novel therapeutic target for glucose regulation.
diabetesjournals.org/diabetes/art...
diabetesjournals.org/diabetes/art...
Towards reducing the already low risk of peri-procedural GLP-1 medicines linked aspiration. Fasting duration, rather than time since last GLP-1 dose, is a key determinant of retained gastric solid content link.springer.com/article/10.1...
November 21, 2025 at 11:22 AM
Towards reducing the already low risk of peri-procedural GLP-1 medicines linked aspiration. Fasting duration, rather than time since last GLP-1 dose, is a key determinant of retained gastric solid content link.springer.com/article/10.1...
A small P2 trial of 24 patients with #T1D randomized to placebo vs. Tirzepatide. Meaningful #weightloss without SAEs
diabetesjournals.org/care/article... ada.silverchair-cdn.com/ada/content_...
diabetesjournals.org/care/article... ada.silverchair-cdn.com/ada/content_...
November 20, 2025 at 10:14 PM
A small P2 trial of 24 patients with #T1D randomized to placebo vs. Tirzepatide. Meaningful #weightloss without SAEs
diabetesjournals.org/care/article... ada.silverchair-cdn.com/ada/content_...
diabetesjournals.org/care/article... ada.silverchair-cdn.com/ada/content_...
A spotlight on key concepts defining postprandial glucagon metabolism in people with and without type 1 #diabetes diabetesjournals.org/diabetes/art...
November 20, 2025 at 9:46 PM
A spotlight on key concepts defining postprandial glucagon metabolism in people with and without type 1 #diabetes diabetesjournals.org/diabetes/art...
Here using #genetics proxies and association with measurable GLP-1R dependent variables, the authors dismiss the non-metabolic roles of GLP1R in relevant cardiovascular tissues for GLP-1R dependent cardioprotection diabetesjournals.org/care/article... ada.silverchair-cdn.com/ada/content_...
November 19, 2025 at 10:11 PM
Here using #genetics proxies and association with measurable GLP-1R dependent variables, the authors dismiss the non-metabolic roles of GLP1R in relevant cardiovascular tissues for GLP-1R dependent cardioprotection diabetesjournals.org/care/article... ada.silverchair-cdn.com/ada/content_...
The consequences of misinformation are real and often tragic #vaccines #measles www.nature.com/articles/d41...
November 19, 2025 at 11:32 AM
The consequences of misinformation are real and often tragic #vaccines #measles www.nature.com/articles/d41...
An update on the Neural Regulation of Blood Glucose in Acute Stress from Professor Stanley @AmDiabetesAssn diabetesjournals.org/diabetes/art...
November 18, 2025 at 10:45 PM
An update on the Neural Regulation of Blood Glucose in Acute Stress from Professor Stanley @AmDiabetesAssn diabetesjournals.org/diabetes/art...
New insights into islet ER stress responses, proinsulin biosynthesis, ERAD and ERD1 using β-cell-specific Hrd1-KO mice & rodent (and human islet) β-cells treated acutely with HRD1 inhibitor. jci.org/articles/vie...
@jci.org
@jci.org
November 18, 2025 at 7:39 PM
New insights into islet ER stress responses, proinsulin biosynthesis, ERAD and ERD1 using β-cell-specific Hrd1-KO mice & rodent (and human islet) β-cells treated acutely with HRD1 inhibitor. jci.org/articles/vie...
@jci.org
@jci.org
Revisiting the traditional paradigms and goals for initial management of #T2D A focus on achievement of #weightloss with cost effective GLP-1 medicines diabetesjournals.org/care/article... ada.silverchair-cdn.com/ada/content_...
November 17, 2025 at 11:49 AM
Revisiting the traditional paradigms and goals for initial management of #T2D A focus on achievement of #weightloss with cost effective GLP-1 medicines diabetesjournals.org/care/article... ada.silverchair-cdn.com/ada/content_...
Giants in #diabetes science recognized with awards at the Levine-Riggs symposium. Congratulations to Dr. Kevan Herold @Yale and Dr. Alvin Powers @VanderbiltU Thank you for your innovation and dedication to rigorous translational diabetes science #T1D #T2D www.cityofhope.org/research/rig...
November 15, 2025 at 11:58 AM
Giants in #diabetes science recognized with awards at the Levine-Riggs symposium. Congratulations to Dr. Kevan Herold @Yale and Dr. Alvin Powers @VanderbiltU Thank you for your innovation and dedication to rigorous translational diabetes science #T1D #T2D www.cityofhope.org/research/rig...
Based on extensive mouse studies
demonstrating miR-432 exacerbates #obesity induced dysregulation of glucose and lipid metabolism, the authors propose miR-342 antagonist to treat cardiometabolic disorders diabetesjournals.org/diabetes/art... ada.silverchair-cdn.com/ada/content_...
demonstrating miR-432 exacerbates #obesity induced dysregulation of glucose and lipid metabolism, the authors propose miR-342 antagonist to treat cardiometabolic disorders diabetesjournals.org/diabetes/art... ada.silverchair-cdn.com/ada/content_...
November 13, 2025 at 1:37 AM
Based on extensive mouse studies
demonstrating miR-432 exacerbates #obesity induced dysregulation of glucose and lipid metabolism, the authors propose miR-342 antagonist to treat cardiometabolic disorders diabetesjournals.org/diabetes/art... ada.silverchair-cdn.com/ada/content_...
demonstrating miR-432 exacerbates #obesity induced dysregulation of glucose and lipid metabolism, the authors propose miR-342 antagonist to treat cardiometabolic disorders diabetesjournals.org/diabetes/art... ada.silverchair-cdn.com/ada/content_...
Thank you to our veterans and active service members, we appreciate your sacrifice
November 11, 2025 at 11:04 AM
Thank you to our veterans and active service members, we appreciate your sacrifice
Some but not all of the remarkable actions of GLP-1 medicines are not strictly dependent on #weightloss findings with real clinical implications #MASH www.novonordisk.com/content/nnco... @aasldnews.bsky.social
November 10, 2025 at 1:53 PM
Some but not all of the remarkable actions of GLP-1 medicines are not strictly dependent on #weightloss findings with real clinical implications #MASH www.novonordisk.com/content/nnco... @aasldnews.bsky.social
Gut barrier function, systemic inflammation and the pathophysiology of metabolic disorders #T2D #obesity journals.physiology.org/doi/abs/10.1...
November 9, 2025 at 12:17 PM
Gut barrier function, systemic inflammation and the pathophysiology of metabolic disorders #T2D #obesity journals.physiology.org/doi/abs/10.1...
Based on preclinical studies with a glucokinase activator the authors propose that targeting immunometabolic pathways may offer a therapeutic strategy to alleviate cardiac dysfunction and reduce infarct vulnerability in #T2D www.biorxiv.org/content/10.1...
November 8, 2025 at 12:04 PM
Based on preclinical studies with a glucokinase activator the authors propose that targeting immunometabolic pathways may offer a therapeutic strategy to alleviate cardiac dysfunction and reduce infarct vulnerability in #T2D www.biorxiv.org/content/10.1...
An update on Teplizumab, a new era for #T1D prevention and management diabetesjournals.org/care/article...
November 6, 2025 at 11:04 PM
An update on Teplizumab, a new era for #T1D prevention and management diabetesjournals.org/care/article...
Studies in mice lead to the proposal that combined treatment with GKA and incretin mimetics may be useful in GCK-MODY and in more common forms of type 2 #diabetes diabetesjournals.org/diabetes/art...
November 6, 2025 at 11:02 PM
Studies in mice lead to the proposal that combined treatment with GKA and incretin mimetics may be useful in GCK-MODY and in more common forms of type 2 #diabetes diabetesjournals.org/diabetes/art...
Eloralintide moves the needle for Amylin agonism #weightloss #obesity in P2 trials investor.lilly.com/news-release... #OW2025
November 6, 2025 at 11:57 AM
Eloralintide moves the needle for Amylin agonism #weightloss #obesity in P2 trials investor.lilly.com/news-release... #OW2025